

- 0179.202105046.
- [3] LIU J F, ZHENG L K, CHENG Y J, et al. Trends in outcomes of patients with ischemic stroke treated between 2002 and 2016: insights from a Chinese cohort [J]. *Circ Cardiovasc Qual Outcomes*, 2019, 12 (12): e005610. DOI: 10.1161/CIRCOUTCOMES.119.005610.
- [4] LEVINE D N, BROOKS M B. Immune thrombocytopenia (ITP): pathophysiology update and diagnostic dilemmas [J]. *Vet Clin Pathol*, 2019, 48 (Suppl 1): 17–28. DOI: 10.1111/vep.12774.
- [5] CORTELAZZO S, FINAZZI G, BUELLI M, et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura [J]. *Blood*, 1991, 77 (1): 31–33.
- [6] Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) results [EB/OL]. [2023-01-20]. <http://ghdx.healthdata.org/gbd-results-tool>.
- [7] RING E, AMMER K. Infrared thermal imaging in medicine [J]. *Physiol Meas*, 2012, 33: R33–46. DOI: 10.1088/0967-3334/33/3/R33.
- [8] 张冉, 朱胜群, 瞿强, 等. 红外热成像技术在西医学领域的研究进展 [J]. *中国卫生产业*, 2019, 16 (4): 197–198.
- [9] YONG M, SCHOONEN W M, LI L, et al. Epidemiology of paediatric immune thrombocytopenia in the general practice research database [J]. *Br J Haematol*, 2010, 149 (6): 855–864. DOI: 10.1111/j.1365-2141.2010.08176.x.
- [10] DEANE S, TEUBER S S, GERSHWIN M E. The geoepidemiology of immune thrombocytopenic purpura [J]. *Autoimmun Rev*, 2010, 9 (5): A342–349. DOI: 10.1016/j.autrev.2009.11.020.
- [11] PARK H K, LEE S H. Ischemic stroke associated with immune thrombocytopenia: lesion patterns and characteristics [J]. *Neurol Sci*, 2014, 35 (11): 1801–1806. DOI: 10.1007/s10072-014-1843-0.
- [12] JY W, HORSTMAN L L, ARCE M, et al. Clinical significance of platelet microparticles in autoimmune thrombocytopenias [J]. *J Lab Clin Med*, 1992, 119 (4): 334–345.
- [13] RHEE H Y, CHOI H Y, KIM S B, et al. Recurrent ischemic stroke in a patient with idiopathic thrombocytopenic purpura [J]. *J Thromb Thrombolysis*, 2010, 30 (2): 229–232. DOI: 10.1007/s11239-009-0431-2.
- [14] AHN Y S, HORSTMAN L L, JY W, et al. Vascular dementia in patients with immune thrombocytopenic purpura [J]. *Thromb Res*, 2002, 107 (6): 337–344. DOI: 10.1016/s0049-3848(02)00337-7.
- [15] ALEDORT L M, HAYWARD C P, CHEN M G, et al. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies [J]. *Am J Hematol*, 2004, 76 (3): 205–213. DOI: 10.1002/ajh.20104.
- [16] MOHREN M, MARKMANN I, DWORSCHAK U, et al. Thromboembolic complications after splenectomy for hematologic diseases [J]. *Am J Hematol*, 2004, 76 (2): 143–147. DOI: 10.1002/ajh.20018.
- [17] RODEGHIERO F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP [J]. *Br J Haematol*, 2018, 181 (2): 183–195. DOI: 10.1111/bjh.15090.
- [18] EMERSON G G, HERNDON C N, SREIH A G. Thrombotic complications after intravenous immunoglobulin therapy in two patients [J]. *Pharmacother J Hum Pharmacol Drug Ther*, 2002, 22 (12): 1638–1641. DOI: 10.1592/phco.22.17.1638.34125.
- [19] ALVARADO R G, LIU J Y, ZWOLAK R M. Danazol and limb-threatening arterial thrombosis: two case reports [J]. *J Vasc Surg*, 2001, 34 (6): 1123–1126. DOI: 10.1067/mva.2001.118078.
- [20] FREEDMAN J E, LOSCALZO J. Nitric oxide and its relationship to thrombotic disorders [J]. *J Thromb Haemost*, 2003, 1 (6): 1183–1188. DOI: 10.1046/j.1538-7836.2003.00180.x.
- [21] DIZ-KÜÇÜKKAYA R, HACIHANEFİOĞLU A, YENEREL M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study [J]. *Blood*, 2001, 98 (6): 1760–1764. DOI: 10.1182/blood.v98.6.1760.
- [22] STEIN R S, FLEXNER J M. Idiopathic thrombocytopenic Purpura during remission of thrombotic thrombocytopenic Purpura [J]. *South Med J*, 1984, 77 (12): 1599–1601. DOI: 10.1097/00007611-198412000-00034.
- [23] OLENICH M, SCHATTNER E. Postpartum thrombotic thrombocytopenic purpura (TTP) complicating pregnancy-associated immune thrombocytopenic purpura (ITP) [J]. *Ann Intern Med*, 1994, 120 (10): 845–847. DOI: 10.7326/0003-4819-120-10-199405150-00005.
- [24] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018 [J]. *中华神经科杂志*, 2018, 51 (9): 666–682. DOI: 10.3760/cma.j.issn.1006-7876.2018.09.004.
- [25] JAUCH E C, SAVER J L, ADAMS JR H P, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [J]. *Stroke*, 2013, 44 (3): 870–947. DOI: 10.1161/STR.0b013e318284056a.
- [26] DEMAERSCHALK B M, KLEINDORFER D O, ADEOYE O M, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association [J]. *Stroke*, 2016, 47 (2): 581–641. DOI: 10.1161/STR.0000000000000086.
- [27] BOULANGER J M, LINDSAY M P, GUBITZ G, et al. Canadian stroke best practice recommendations for acute stroke management: prehospital, emergency department, and acute inpatient stroke care, 6th edition, update 2018 [J]. *Int J Stroke*, 2018, 13 (9): 949–984. DOI: 10.1177/1747493018786616.
- [28] THACHIL J, CALLAGHAN T, MARTLEW V. Thromboembolic events are not uncommon in patients with immune thrombocytopenia [J]. *Br J Haematol*, 2010, 150 (4): 496–497. DOI: 10.1111/j.1365-2141.2010.08234.x.
- [29] LU J, HU P, WEI G Y, et al. Effect of alteplase on platelet function and receptor expression [J]. *J Int Med Res*, 2019, 47